Skip to content
value.today

Celator Pharmaceuticals Inc

🇺🇸 Princeton, New Jersey, USAPharmaceuticalsFounded 2005
Total raised
$59 M
4 rounds on record
Latest round
$39 M
Aug 2012
First round on record
May 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Celator Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2012$39 MNo. 4$10 to $50 million

Celator Pharmaceuticals Inc: Raise no. 4, Aug 2012

Investors in this round

306 investors had bought by the notice of May 13, 2013: 306 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$39 M of $39 M offered
Smallest investment taken
$22,500
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$3,432,458
Finders' fees
none
Paid to its own people
$4,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fred M. Powell · Executive Officer
  • Jackson T. Scott · Executive Officer, Director
  • Lawrence T. Mayer · Executive Officer
  • Alex S. Zisson · Director
  • Joseph A. Mollica · Director
  • Kenneth A. Galbraith · Director
  • Nicole S. Vitullo · Director
  • Richard S. Kollender · Director
  • Scott S. Morenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states
  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in MA, NJ, NY

Remarks in the notice

  • On the use of proceeds: “Represents estimated salary payments over a period of 48 months.”

Signed by Fred M. Powell, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 13, 2013. Read the notice at the SEC.

equity, optionsSEC
Dec 2011$3 MNo. 3$2 to $10 million

Celator Pharmaceuticals Inc: Raise no. 3, Dec 2011

Investors in this round

10 investors had bought by the notice of Dec 28, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$450,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David D Wood · Executive Officer
  • Lawrence D Mayer · Executive Officer
  • Scott Jackson · Executive Officer, Director
  • Alex D Zisson · Director
  • Brenda D Gavin, D.V.M. · Director
  • Joseph A. Molliica, Ph.D. · Director
  • Kenneth Galbraith · Director
  • Nicole D Vitullo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Jacson, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 28, 2011. Read the notice at the SEC.

equity, optionsSEC
Aug 2010$15 MNo. 2$10 to $50 million

Celator Pharmaceuticals Inc: Raise no. 2, Aug 2010

Investors in this round

12 investors had bought by the notice of Sep 7, 2010: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $20 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,267,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David D. Wood · Executive Officer
  • Lawrence D. Mayer · Executive Officer
  • Scott Jackson · Executive Officer, Director
  • Alex D. Zisson · Director
  • Brenda D. Gavin · Director
  • J. Kevin Buchi · Director
  • Joseph A. Mollica · Director
  • Kenneth Kevin Galbraith · Director
  • Nicole A. Vitullo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes Series D Preferred Stock representing, in the aggregate, an amount of approximately $2,560,274 that were issued to certain stockholders upon conversion of the principal amount and accrued interest under convertible promissory notes.”

Signed by Scott Jackson, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 7, 2010. Read the notice at the SEC.

equity, optionsSEC
May 2010$3 MNo. 1$2 to $10 million

Celator Pharmaceuticals Inc: Raise no. 1, May 2010

Investors in this round

9 investors had bought by the notice of May 10, 2010: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David D. Wood · Executive Officer
  • Lawrence D. Mayer · Executive Officer, Director
  • Scott Jackson · Executive Officer, Director
  • Brenda D. Gavin · Director
  • J. Kevin Buchi · Director
  • Joseph A. Mollica · Director
  • Kenneth Kevin Galbraith · Director
  • Nicole A. Vitullo · Director
  • Patrick D. Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Jackson, Chief Executive Officer. Source: SEC Form D, newest notice filed May 10, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Celator Pharmaceuticals Inc had revenue of up to $1 million when it filed its newest notice of a funding round (May 2013).

    SEC Form D (revenue range) · May 2013

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2010; revenue between $5 million and $25 million in 2011; revenue of up to $1 million in 2013.

    SEC Form D (revenue range) · May 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2013

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Celator Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 306 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Celator Pharmaceuticals Inc
NameRoleNamed in
Fred M. PowellExecutive officerMay 2013
Jackson T. ScottExecutive officerMay 2013
Lawrence T. MayerExecutive officerMay 2013
David T. WoodExecutive officerAug 2012
David D WoodExecutive officerDec 2011
Lawrence D MayerExecutive officerDec 2011
Scott JacksonExecutive officerDec 2011
David D. WoodExecutive officerSep 2010
Lawrence D. MayerExecutive officerSep 2010
Alex S. ZissonDirectorMay 2013
Jackson T. ScottDirectorMay 2013
Joseph A. MollicaDirectorMay 2013
Kenneth A. GalbraithDirectorMay 2013
Nicole S. VitulloDirectorMay 2013
Richard S. KollenderDirectorMay 2013
Scott S. MorensteinDirectorMay 2013
Alex D ZissonDirectorDec 2011
Brenda D Gavin, D.V.M.DirectorDec 2011
Joseph A. Molliica, Ph.D.DirectorDec 2011
Kenneth GalbraithDirectorDec 2011
Nicole D VitulloDirectorDec 2011
Scott JacksonDirectorDec 2011
Alex D. ZissonDirectorSep 2010
Brenda D. GavinDirectorSep 2010
J. Kevin BuchiDirectorSep 2010
Kenneth Kevin GalbraithDirectorSep 2010
Nicole A. VitulloDirectorSep 2010
Lawrence D. MayerDirectorMay 2010
Patrick D. BradyDirectorMay 2010